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Background: In a competing risks framework where a subject is exposed to more than one 
cause of failure, multiple or tied ‘first’ failures may be detected simultaneously at a particular 
follow-up. This is often observed in cancer clinical trials in which patients are usually 
investigated periodically. Consecutive failures are likely to be detected at the same visit if the 
investigation period is relatively long. If the tied failures are substantial, standard competing 
risks analysis methods such as cause-specific hazard regression may not be applied 
satisfactorily as considerable information is missing due to the unknown cause of failure. 
Methods: We developed a shared frailty model to identify the ‘true’ cause of failure in the 
event of ties by taking into account information on distinct failures and the dependence 
between multiple failures arising from the same subject. We conducted extensive simulation 
studies to evaluate the performance of the proposed method with regards to the parameter 
estimation and the identification of ‘true’ cause of failure. The shared frailty method was 
further applied to the data from a randomised clinical trial of paediatrics with osteosarcoma 
(Souhami et al. 1997) to evaluate the treatment effect of a double-drug regimen of 
chemotherapy versus a multiple-drug regimen in association with the time to development of 
lung-metastasis and non lung-metastasis. 
Results: The simulation results demonstrated accuracy, efficiency and robustness of the 
proposed method in the parameter estimation, and improved accuracy in identifying the ‘true’ 
cause failure compared to existing methods. The analysis of the osteosarcoma data using the 
shared frailty model generally produced similar estimated number of events, treatment effects 
and SEs as existing methods, indicating that the double-drug regimen had similar treatment 
effect as the multiple-drug regimen.  
viii 
 
Conclusion: The proposed shared frailty model generally improves the accuracy of 
identifying the ‘true’ cause of failure in the event of ties and is more robust in estimating the 
covariate effect as compared to existing methods. However, it is sensitive to the length of 











CHAPTER 1  
      Introduction 
1.1 COMPETING RISKS 
In biomedical research where time-to-event is of interest, there may only be a single type of 
failure for each study subject. Survival analysis is the standard method for dealing with this 
kind of data (Kalbfleisch and Prentice 2002). Figure 1.1 depicts a typical survival analysis 
problem where all-cause mortality is defined as the endpoint. A subject experiences a failure 
if he/she moves from state 0 (alive) from the beginning of the study to state 1 (death of any 
cause). Otherwise, he/she will be censored (Schulgen et al. 2005). 
 
 
More generally, a subject may experience one of m distinct types of failure which are 
commonly referred to as competing risks. A subject typically has information of the failure 
time T ≥ 0 which may be subject to censoring, and the failure type             which is 
unknown when T is censored. There may also be a vector of covariates                
recording demographic and clinical characteristics of the subject such as age, gender, and 
treatment allocated. Some covariates are time dependent, that is       , as they may 
change or are measured repeatedly over time (Prentice and Kalbfleisch 1978). Figure 1.2 
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displays a demographic mortality study where different causes of death are categorized into 
cancer, heart disease and death from other causes. A subject may move from state 0 (alive) to 
any of the three absorbing states 1, 2 or 3 (Kalbfleisch and Prentice 2002). 
 
 
Competing risks analysis allows evaluation of covariate effects, such as treatment effect, on 
subgroups of subjects with different endpoints. This facilitates the allocation of treatment to a 





There are three general questions competing risks analysis attempts to answer: (1) what is the 
association between some covariates, e.g. treatment, and a specific type of failure, (2) is there 
any dependence among failure types under a certain condition, and (3) given the removal of 
some or all other failure types, what is the failure rate of a specific failure type (Prentice and 
Kalbfleisch 1978). 
 
1.2 COMPETING RISKS METHODS 
1.2.1 Cause-specific Hazard Function 
Various approaches have been suggested in competing risks analysis. One intuitive way is to 
use the cause-specific hazard function (Chiang 1968, 1970, and Altshuler 1970) which is 
defined as 
        
   
    
                     
  
                        
The function         represents the instantaneous failure rate from cause j at time t in the 
presence of other failure types, given a covariate vector x. In the context of competing risks, 
the Cox proportional hazard model is often used to evaluate the covariate effects (Holt 1978, 
Pretence and Breslow 1978) and is defined as follow 
                 (   )                         
where         is the baseline hazard function and βj is a column vector of covariate 
coefficients of cause j. This model does not assume any dependence among failure types.  
Moreover, interpretation of covariate effects is only valid under conditions of the study. 
Equivalently, it does not imply the failure rate with removal of some or all other failure types. 
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Lastly, the model of cause j does not restrict the proportional hazard form of other failure 
types. 
 
1.2.2 Accelerated Failure Time Model 
Alternatively, the accelerated failure time model may be incorporated in estimating the cause-
specific hazard function. However, this model is applicable only to time-independent 
covariates as shown 
           [    (   )]    (   )                        
Both parametric and non-parametric approaches have been discussed in the literature on the 
inference of βj (Gehan 1965, Mantel 1966, Farewell and Pretence 1977, and Pretence 1978). 
 
1.2.3 Cumulative Incidence Function 
Cumulative incidence function has also been advocated to describe competing risks (Fine and 
Gray 1999). It is defined as  
                                            






Based on the proportional hazards assumption, this probability can be further written as 
shown 
             [ ∫          (   )
 
 
  ]                         
 
1.2.4 Latent Failure Time Model 
Some authors described competing risks in terms of latent failure times (Cox 1959, 
Moeschberger and David 1971). Suppose Y1, Y2, …, Ym are failure times of cause 1 to m, and 
Yj is the observed failure time for the cause j for a subject. A paired observation (T, J) is 
recorded for a subject who experienced failure type j, where 
                      { |             }           
A joint survivor function, or multiple decrement, is postulated as follow 
                                          
It has been shown that only the diagonal derivatives of logQ are estimable, whereas the 
marginal and joint survivor functions are not identifiable (Cox 1959, Berman 1963 and Gail 
1975). Hence, the study of dependence using the latent failure time model is not established 
without further assumptions. 
 
1.3 TIED FAILURES IN COMPETING RISKS  
1.3.1 Example from the Literature  
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The above methods can only be implemented if the cause of failure is known. However in 
some situations, multiple failures may be diagnosed simultaneously in a patient. This brings 
new challenges to the application of standard competing risks methods. For instance in a 
study of limited small-cell lung carcinoma (LSCLC) (Arriagada et al. 1992), the main aim 
was to compare four treatment protocols in terms of time to first relapse. Relapse was defined 
as local recurrence (LR), distant metastasis (DM) or death unrelated to cancer. Table 1.1 
shows that overall, 66 LR, 49 DM and 16 deaths occurred at the end of study. Nineteen 
patients were diagnosed with LR and DM simultaneously. 
Table 1.1 Types of Failure According to Treatment  
 Treatment groups  
 A  
(n = 28) 
B  
(n = 81) 
C  
(n = 64) 
D  
(n = 29) 
Total  
(n = 202) 
Type of failure N (%) N (%) N (%) N (%) N (%) 
LR 9  (32.1) 27  (33.3)    21  (33.1) 9  (31.4) 66  (32.7) 
DM 6  (21.4) 24  (29.6) 14  (22.6) 5  (17.2) 49  (24.3) 
LR and DM 3  (10.7) 5  (6.2) 9  (14.3) 2  (6.9) 19  (9.4) 
Death without cancer 1  (3.6) 5  (6.2) 5  (7.9) 5  (18.5) 16  (7.9) 
 
 
As pointed out by Tai et al. (2002), the multiple failures are most likely to have occurred 
because of measurement inaccuracy, rather than different types of failure happening exactly 
at the same time. Although Arriagada et al. (1992) did not provide any detail on patients’ 
follow-up, many similar studies had indicated that their follow-up or measurement of disease 
status were not in high frequency. Purohit et al. (1995) recommended three-month intervals 
for clinical examination, Chest X-ray, brain and thorax computed axial tomographic (CAT) 
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scans, and six-month intervals for abdominal ultrasound and upper abdomen CAT scan for 
patients with LSCLC. Similarly, Work et al. (1996) suggested evaluating patients with 
LSCLC every 3-4 months. More examples on follow-up schedules of lung cancer can be 
found in Trillet-Lenoir et al. (1993), Brewster et al. (1995), and Hainsworth et al. (1996) 
where patients were arranged for systematic examination on a monthly interval or longer.  
 
Following the example of Arriagada et al. (1992), for those diagnosed with multiple relapses, 
either LR or DM could have been detected earlier if follow-up was more frequent. However, 
the true cause of first relapse was missing in this instance. For those diagnosed with distinct 
relapses, the failures were more likely to occur before the scheduled follow-up rather than on 
the follow-up visit itself. Although failure times are frequently viewed as right censored data, 
they could be interval censored in a strict sense. Let i and i + 1 be two consecutive 
investigation time and assume that no event was detected prior to time i. Figure 1.3 
demonstrates five different scenarios when a first failure could occur in a patient between the 
investigation times i and i + 1: (a) a patient had LR between visit i and visit i + 1; (b) a 
patient developed DM between visit i and visit i + 1; (c) a patient died between visit i and 
visit i + 1; (d) a patient had both LR and DM in the i + 1
th 
interval, while no relapse was 
found at the i
th 
interval; and (e) a patient was diagnosed with both DM and LR at the i + 1
th 
interval, with no relapse was found at the i
th
 interval. Multiple or ‘tied’ failures were observed 
in scenarios (d) and (e), with both LR and DM being reported in visit i + 1. As depicted in 








1.3.2 Motivation of the Study 
In clinical trials where patients may develop more than one type of failure, the first failure is 
often of primary interest as mechanisms of subsequent failures may be altered if the first has 
occurred (Pintilie 2006). Therefore, to evaluate treatment effect on a particular disease, first 
failure is usually a more appropriate indicator as compared to subsequent failures. Moreover, 
some studies emphasise one type of failure more than others. For example, as noted by 
Arriagada et al. (1992), investigators were often particularly interested in examining LR 
although three types of relapses were defined as study endpoints. Thus, it is clinically 
important to distinguish the risk of interest from the other types of failures. 
 
The presence of tied failures complicates the competing risks analysis. Tai et al. (2002) 
provided an example of a randomised trial comparing two regimens of chemotherapy in 
operable osteosarcoma based on the data of Souhami et al. (1997). A detailed description of 
this study is provided in section 4.2. The endpoints of interests were overall and progression-
free survival. The various types of relapse were LR, lung metastasis (LM) and other 
metastasis (OM). Tai et al. (2002) reviewed the 402 participants retrospectively and identified 
17 LR, 153 LM and 18 OM as distinct first relapses. Multiple relapses were diagnosed 
simultaneously in 36 patients. Thus comparing the treatment effect of the two regimens using 
competing risks methods is not straightforward in this case, as the true cause of first failure is 
unknown for approximately 16 percent of first relapses. Moreover, it may be clinically 
difficult to interpret the group with tied failures, for example, LR and OM. Besides, the 
number of distinct failures will be underestimated in the presence of tied failures. This may 
result in larger standard errors of estimates if the ties are substantial.   
    
10 
 
Hence from both clinical and statistical points of view, it is important to tackle the tied 
failures before standard competing risks methods may be implemented. 
 
1.4 OBJECTIVE AND OUTLINE OF THE STUDY 
1.4.1 Objective 
The aim of this study is to develop methods for handling tied failures in competing risks 
analysis in order to identify the true cause of failure in the presence of ties. Standard 
competing risks analysis such as the cause-specific hazard regression can then be 
implemented to evaluate covariate effects. 
 
1.4.2 Outline 
The thesis is organised in the following manner. In the remaining of this chapter, a literature 
review for handling tied failures and missing cause of failure will be covered, and the 
advantages and potential limitations of the existing methods will be discussed. Chapter 2 
introduces the parametric modelling of tied failures in competing risks analysis. More 
specifically, section 2.1 describes the proposed model for handling tied failures, and section 
2.2 covers the technical details on the construction of the likelihood function in the presence 
of ties and interval censoring and the parameter estimation procedure. This is followed by 
section 2.3 which illustrates the imputation of the unknown first failure in the event of ties. 
Simulation studies that aim to assess the performance of the proposed method are presented 
in Chapter 3. Section 3.1 demonstrated the essential steps of generating a competing risks 
dataset containing tied failures, while sections 3.2 and 3.3 evaluate the performance of the 
proposed method with respect to the parameter estimation and identification of the unknown 
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first failure respectively. Some issues related to the simulation studies are discussed in section 
3.4. In Chapter 4, we apply the proposed method to the data from a randomised clinical trial 
of paediatrics with osteosarcoma (Souhami et al. 1997). A detailed data description is given 
in section 4.1. In section 4.2, the data is analysed using the proposed method and the results 
are compared with those obtained using the methods proposed by Tai et al. (2002) both of 
which assume random allocation of tied events. The last section 4.3 provides a discussion on 
issues relating to the data analysis in section 4.2. Chapter 5 reviews the findings reported in 
Chapters 3 and 4, and further discusses the strengths and limitations of our proposed method. 
Last but not least, the thesis concludes with several suggestions for potential future work.     
 
1.5 LITERATUR REVIEW  
1.5.1 Tied Failures in Competing Risks Analysis 
Tied failures are frequently encountered in cancer studies where patients are followed up 
systematically.  In their LSCLC study, Arriagada et al. (1992) considered patients diagnosed 
with both LR and DM as a distinct group, and compared treatment effects across four 
protocols using the cause-specific hazard function. LR, DM, death, and tied failures were 
treated as four competing causes of failure in the analysis.  
 
Klein et al. (1989) provided two examples where they applied a semi-parametric Marshall-
Olkin model to assess covariates which might have different effects on different types of 
failure based on a study of the Danish Breast Cancer Cooperative Group (Andersen et al. 
1981). A total of 1,275 high-risk postmenopausal patients were involved in this study with 
three treatment groups. First relapse was categorized into 10 different types. In the first 
12 
 
example, Klein et al. (1989) compared the covariate effect on bone metastasis against a 
combination of nine other failures. Bone metastases were exclusively detected in 85 patients, 
while 218 patients had metastases that were not bone. Forty-four patients were observed to 
have metastases at the bone and other sites simultaneously. Similarly, their second example 
compared treatment effect on lung metastasis versus metastasis of other skin, the detailed 
definition of the latter can be found in Andersen et al. (1981). Seventeen patients developed 
metastases of other skin, and 91 of them had lung metastases. Both lung and other skin 
metastases were detected in eight patients. For the purpose of analysis, Klein et al. (1989) 
considered patients with tied failures as a single category. As a result, they compared 
treatment effects on the two types of failure with three competing risks, namely, lung 
metastasis, other skin metastasis and tied failures.  
 
In a phase II trial for unresectable stage III non-small cell lung cancer, Chang et al. (2011) 
investigated the effect of high dose proton therapy with weekly concurrent chemotherapy in 
prolonging patients’ overall and progression-free survival. Secondary endpoint included local 
progression-free survival, whereas regional recurrence (RR) and DM were regarded as 
competing events. Patients were evaluated every six weeks upon completion of proton 
therapy, at three months for two years and six months thereafter. Among 44 patients who 
participated in the study, 25 of them had one or more first relapses. Of the nine patients who 
had LR, five of them were also diagnosed with RR and/or DM simultaneously. Four patients 
were found to have RR, but three of them were observed together with LR and/or DM. 
Nineteen patients failed from DM, while five of them were diagnosed with LR and/or RR as 
their first relapses. The study did not clarify how the tied failures were handled, although 
more than 50% of LR occurred simultaneously with other first relapses. The local 
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progression-free survival curve implicitly showed that tied first failures including LR were 
treated as distinct LR.  
 
Kriege et al. (2008) also presented a large number of tied failures in their breast cancer study, 
where the objectives were to compare distant disease-free intervals, sites of first DM and 
post-relapse survival between BRCA1-associated, BRCA2-associated and sporadic breast 
cancer patients. A total of 772 (223 BRCA1-assocated, 103 BRCA2-associated, and 446 
sporadic) patients who received radiotherapy along with adjuvant systemic treatment were 
followed up between 1980 and 2004. Sites of DM were either lymph nodes, skin, bone, liver, 
lung, pleura, brain, or other. However, unknown sites of failures were also reported. Fifty-
seven BRCA1-associated, 31 BRCA2-associated and 192 sporadic patients were diagnosed 
with DM. Of these, 25 BRCA1-associated, 15 BRCA2-associated, and 62 sporadic patients 
were detected DM at multiple sites simultaneously.  In comparing the sites of first DM across 
the three subgroups, the tied failures were treated as a single category.  
 
More examples on tied failures can be found in Subotic et al. (2009) and Sasako et al. (2011). 
In view of the above clinical studies, it can be seen that the issue of tied failures has not been 
addressed adequately in medical literature. Tied failures were often treated as a new category, 
or simply ignored in the analysis. Sometimes, they were combined with a distinct failure type 
when the number of distinct failures was small.   
 
The term ‘multiple first failures’ or ‘tied first failures’ appeared for the first time in Tai et al. 
(2002). They formally introduced the concept of tied failures, discussed and formulated the 
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problem in the framework of competing risks analysis. Instead of grouping tied failures into a 
single category, they put effort into breaking the ties. Two methods were recommended in 
their paper. Weighted Cox regression (WC) assigns a weight which is equal to the reciprocal 
of the number of ties to each tied failure. The weight for a distinct failure is one. Then a 
weighted Cox regression is implemented in standard statistical software with a specification 
of a weighting factor. As subjects with tied failures now have multiple observations, 
correlation among observations needs to be adjusted. The STATA program employs a 
sandwich estimator of variance to accommodate the clustering effect of observations from the 
same subject. The variance is a modified version of the robust estimator of variance, with 
additional weights denoting the contribution of each cluster to the overall likelihood function 
(STATA/SE 11.0). 
 
Jittering method (JM) randomly adds a small number, r, to the time Tj of failure type j in the 
tie, so that forces an order for tied failures. 
 ̃                 
where          , and    . They recommended a to take any value less than half of the 
smallest time interval of two successive events. To avoid underestimation of the variability of 
estimates due to uncertainty of single imputation, they suggested a multiple imputation 
procedure based on the method of Rubin and Schenker (1991). 
 
Simulation studies showed that JM was practically safe, and theoretically reasonable as it 
imposed small variability using multiple imputation. WC generated smaller standard errors as 
compared to JM, because it ignored the order of tied failures. 
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1.5.2 Missing Cause of Failure in Competing Risks Analysis 
Under the competing risks framework, a subject may fail from one of many causes. However, 
the true case of failure may be missing or restricted to a subset of possible causes (Dewanji 
and Sengupta 2003). Besides tied failures, such a problem is also commonly encountered in 
the medical and statistical literature involving competing risks analysis. For example, the 
Eastern Cooperative Oncology Group conducted a clinical trial comparing two chemotherapy 
regimens on patients with advanced Hodgkin’s disease (Andersen et al. 1996). Of 304 
patients involved in the study, 179 had died at the time of analysis. Data were reviewed 
retrospectively to determine the cause of death. The following competing causes of death 
were established: Hodgkin’s disease, cardiovascular disease, infection, tumor and NHL, and 
leukaemia. Ten patients died from other medical conditions that were not identifiable. This 
accounted for approximately six percent of deaths in total. 
 
As noted by Andersen et al. (1996), clinical trials that are conducted prospectively commonly 
have complete data on patients’ characteristics, such as age, gender, and disease status. 
However, the quality of data generally deteriorates as follow-up goes on. Deaths may be 
reported without death forms fully completed, patients may die without an autopsy, or 
emigrated and so only death status is reported. These thus lead to missing cause of death, or 
death attributed to multiple causes.  
 
Extensive research has been devoted to competing risks analysis with missing cause of failure 
of this nature. Goetghebeur and Ryan (1995) modeled distinct and missing cause of failure 
using cause-specific hazard function. A partial likelihood function is maximized to assess 
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covariate effects, where the missing cause of failure is weighted by a probability which is the 
sum of probabilities of distinct failures. 
 
Lu and Tsiatis (2001) also adopted the cause-specific hazard approach. Suppose T is the 
observed failure time, J the failure type, x a vector of covariates, and z a vector of auxiliary 
variables which may be related to reasons why a cause is missing. Let r be a vector of 
unknown parameters. They imputed the failure of interest for the ith patient by using a 
logistic regression model                 
  , where                   and 
             .  It is assumed that the probability that a cause is missing given the patient’s 
characteristics is independent of the true cause of failure. This is also known as missing at 
random.  A derivation of this assumption allows the estimation of r by maximizing the 
likelihood function of complete observations. Similar imputation procedure was suggested by 
Lu and Liang (2008), although they proposed a semi-parametric additive hazards model for 
analysing competing risks data.  
 
Dewanji and Sengupta (2003) considered competing risks problems nonparametrically. They 
estimated cause-specific hazards in the presence of missing cause of failure through an EM 
algorithm. Moreover, they estimated the cumulative cause-specific hazards by using the 
Nelson-Aalen estimator. To overcome the missing cause of failure, they simply assumed that 
the experimentalist can estimate the probability of a particular failure type, given that a 




Chen and Cook (2009) worked on the problem of multivariate failure time data where an 
event could have occurred, but the cause of failure might be undetermined. Subjects in the 
study were at risk of more than one type of recurrent event. They constructed a cause-specific 
hazard model with a frailty term modeling dependence between different failure types 
   ( |      )                    , where        is the baseline cause-specific hazard,    is 
a vector of covariates of the ith patient, and    is a vector of covariate coefficients. The 
random effect of the cause j,   , is assumed to follow a log-normal distribution. The Gibbs’ 
samples were used to impute the missing cause of failure. 
 
Bayesian methods have also been discussed when dealing with missing cause of failure 
(Reiser et al. 1995, Basu et al. 2003, Sarhan and Kundu 2008, and Basu 2009). However, 
these are mainly implemented for identifying component failure in a system and estimating 
reliability in engineering applications. It is often named as masked cause of failure or masked 
system life data in the statistical literature. The essential idea is to select an appropriate prior 
distribution for the lifetime. A joint distribution of observable and unobservable data can then 
be derived from the reduced likelihood function. The conditional probability of the true cause 
of failure, J = j, in a masked failure can be conveniently expressed in a closed form.  
 
1.6 LIMITATIONS OF EXISTING METHODS 
Handling of tied failures in competing risks analysis has emerged as a new research interest 
only in the last decade. Numerous studies have been performed involving missing cause of 
failure, but little attention has been paid to the problem of tied failures. To-date, only one 
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paper has formally addressed this issue (Tai et al. 2002), even though tied failures are 
frequently encountered in cancer studies as described in section 1.5.1.  
 
Very often, tied failures are regarded as a separate category in the medical literature 
especially when they are substantial (Klein et al. 1989; Arriagada et al. 1992; Kriege et al. 
2008). Indeed, Klein et al. (1989) reported tied failures that constituted an average of ten 
percent of total relapses (13% for example 1 and 7% for example 2). Arriagada et al. (1992) 
also observed simultaneous dual events which accounted for approximately 13 percent of all 
relapses.  More remarkably, an average of 41 percent of tied failures was detected in the 
study of Kriege et al. (2008) (44% for BRCA1-associated, 48% for BRCA2-associated, and 
32% for sporadic breast cancer patients respectively), which was probably a result of long 
follow-up intervals. The disadvantages of this approach have been discussed in section 1.3.2. 
Moreover, simulation studies of Tai et al. (2002) demonstrated that this method produced 
much larger standard errors as compared to WC and JM methods, when there were up to 16 
percent of tied failures. 
 
Chang et al. (2011) implicitly combined tied failures including LR with distinct LR when 
calculating the local progression-free survival. While it may be reasonable to handle ties in 
this manner, especially if the number of distinct failures is small, this approach may not be 
very appropriate in many circumstances. For instance, the study of Klein et al. (1989) 
compared treatment effects on two types of failures. In the presence of tied failures, it could 
be difficult to justify why the tied failures should be combined with one group but not the 
other, as both outcomes were considered equivalently important. Also, for studies with very 
heavy ties such as Kriege et al. (2008), results would change dramatically if we change the 
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combination of tied failures involving three distinct causes. Hence, this approach has to be 
applied with caution.   
 
The WC and JM methods proposed by Tai et al. (2002) are straightforward, and can be 
implemented in standard statistical software. They provide reasonable estimates when events 
are equally likely to occur as the first failure. On the flip side of the coin, the random 
allocation assumption may constrain their uses. In some situations, subjects may be more 
vulnerable to certain type of failure as compared to the rest. An example can be seen in a 
phase III randomised trial of adjuvant tamoxifen therapy for early stage breast cancer in 
postmenstrual women (Goss et al. 2003). The primary interest was to compare the disease-
free survival between patients taking letrozole and placebo. Sites of relapses were primarily 
LR, RR, or DM. DM was found to be the predominant failure (123 cases) as compared to LR 
(34 cases) and RR (10 cases) among the 5,187 participants. That is, patients were around ten 
times as likely to develop DM than LR or RR. Thus, the two methods discussed above may 
not be applied satisfactorily under such scenario.  
 
Although WC and JM are reasonable methods for handling tied failures, the underlying 
assumption is that the failure times are right censored. The assumption may be violated when 
follow-up intervals are relatively long. Besides, it does not reflect the mechanism of the 
formation of ties in the presence of relapses.  
 
JM enforces a rank for the tied failures. Thus it does not assume any dependence among 
failure types in the subsequent competing risks analysis. However, tied failures are likely to 
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be correlated as they occur on the same subject (Liang et al. 1995). Therefore, such 
dependence should be accounted for especially if there are heavy ties. The WC method 
adjusts for dependence of failures from the same subject by using a weighting factor. 
However, it fundamentally assumes that each subject contributes the same weight to the 
likelihood function. This assumption may be too strong for most clinical trials which involve 
human subjects.  
 
1.7 CONTRIBUTION OF THE STUDY 
In this study, we develop methods for handling tied failures in competing risks analysis by 
fully utilising existing information on observed failures. This approach has not been 
considered in previous studies. We further study the dependence between failure types via a 
shared frailty (SF) model. Moreover, the problem will be discussed under the setting of 
interval-censoring in accordance to the formation of ties. Since exact and right-censoring 
times can be viewed as special cases of interval-censored failure times (Sun 2006), our model 
will have more general applications under this assumption.  
 
This study was presented at the 31
st
 Annual Meeting of the International Society of Clinical 
Biostatistics, 21-25 August, 2011 in Ottawa, Canada. 
 
A poster in relation to this study was also presented at the Second Singapore Conference on 
Statistical Science (2011), organised by the Department of Statistics and Applied Probability, 




      Parametric Modelling of Tied Failures in Competing Risks 
Analysis 
In this chapter, we propose a SF model for tackling tied failures in competing risks analysis. 
Without loss of generality, we assume that there are two events, a main event of interest, 
Event 1, and a competing risk, Event 2. We further consider the situation where there is only 
one treatment covariate. The maximum likelihood estimation (MLE) method is used to 
estimate the model parameters using the SAS procedure PROC NLMIXED (SAS 9.2). The 
unknown first failure is then imputed from a Bernoulli distribution with the probability of 
Event 1 or Event 2 being the first failure in the tie as a function of the estimated parameters. 
Standard competing risks methods such as the cause-specific hazard regression may then be 
applied to evaluate the covariates of interest. 
 
2.1 THE SHARED FRAILTY MODEL FOR MODELLING TIED FAILURES 
The cause-specific hazard function is commonly used for analysing competing risks data in 
clinical research due to its ease of interpretation. It also has great flexibility in 
accommodating time-dependent covariates, if the assumption of proportionality is violated 
(Lee and Wang 2003). We propose a parametric model assuming an exponential distribution 
for modelling failure times because of its simplicity since there is only one parameter under 
consideration, which is the hazard rate. As it is a special case of many popular failure time 
distributions, such as the Weibull, Gamma and even piecewise exponential distributions, it 
gives a reasonable exploration of the data and may suggest a more appropriate failure time 
distribution which better fits the data (Lee and Wang 2003). 
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The term ‘frailty’ originates from the early work of Vaupel et al. (1979) which studies 
population heterogeneity in their endowment of longevity. The traditional univariate frailty 
model assesses the unobserved heterogeneity which could not be explained by the observed 
covariates. As its extension, the multivariate frailty model accounts for the dependence or 
correlation of clustered event times, arising from related subjects such as family members or 
recurrent events such as asthma attacks. As compared to the univariate model, the 
multivariate frailty model is more sophisticated in studying the nature of disease and 
mortality process (Wienke 2011). One important and commonly used approach is the SF 
model. It is assumed that given the frailty, failure times in a cluster are conditionally 
independent. Moreover, subjects or events in a cluster share the same frailty which remains 
constant over time (Wienke 2011). The SF model was first discussed in the literature by 
Clayton (1978). He proposed bivariate survivorship time distributions for the analysis of 
familial tendency in chronic disease incidence. Other extensive studies include the 
monographs by Hougaard (2000), and Duchateau and Janssen (2008). Liu et al. (2004) also 
adopted a SF model to study the dependence between recurrent events and a terminal event, 
by including a frailty term in both hazard functions.   
 
We propose to apply the SF model to a competing risks framework and study the dependence 
between tied competing events which may have occurred due to inadequate follow-up. 
Suppose we consider a main event, Event 1, and a competing risk, Event 2, and model the 
time to each event via the cause-specific hazard function. It is assumed that each failure time 
follows an exponential distribution with hazard rate      and      respectively. 
Consider the simplest case where there is only one covariate x, denoting treatment. Let x = 1 
if a subject receives the experimental treatment and x = 0 if the standard treatment is 
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allocated. Assume that there are n subjects enrolled into the study and tied first failures are 
observed in some of them. We propose a SF model for the two events as follows 
                                           
                                     
where    is the frailty of the ith subject, with i = 1, 2, …, n, and    and    are the regression 
coefficients denoting the treatment effect for Event 1 and Event 2 respectively. For 
mathematical convenience,   is assumed to follow a Gamma distribution with mean 1 and 
variance  . This assumption loses no generality as the average level of frailty can always be 
absorbed into the baseline hazards. 
 
2.2 THE MAXIMUM LIKELIHOOD ESTIMATION  
2.2.1 The Likelihood Function 
Assume two investigation times    and   , where      . Let     be the earliest 
investigation time when a failure is detected on the ith subject, or the time of last follow-up if 
no failure has occurred, and     the last investigation time prior to     when no failure is 
detected. The ith subject may experience one of the following four possible outcomes in the 
time interval [   ,    ]: (1) No event; (2) Event 1 only; (3) Event 2 only; (4) Event 1 and 
Event 2. The subject will be diagnosed with tied first failures in scenario (4), regardless of the 




Given the frailty   , the failure time of the two events are conditionally independent for the 
ith subject. Thus, the conditional probability of each of the four outcomes can be derived as 
follow 
 (1) Conditional probability of no event:                     
 
                    
                      
    [                 ]    [                 ]           
 
(2) Conditional probability of Event 1 only:                     
 
                    
 ∫                       
   
   
 
 [                     ]           
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     [                 ]     [                 ]  
        [                 ]           
 
(3) Conditional probability of Event 2 only:                     
 
                    
 ∫                       
   
   
 
 [                     ]           
     [                 ]     [                 ]  
        [                 ]           
 
(4) Conditional probability of tied Event 1 and Event 2:                     
When two events are observed simultaneously at a particular follow-up visit, two possibilities 






                    
 ∫ ∫   
   
   
   
   
                           
 [                     ][                     ] 
     [                 ]     [                 ]  
        [                 ]     [                 ]            
  
Let     be the indicator variable denoting no event has occurred in the time interval [       ] 
for the ith subject. Similarly, define          and     as the indicator variables denoting the 
occurrence of Event 1 only, Event 2 only, and tied Event 1 and Event 2. The conditional 
likelihood function of the ith subject can be written as follow 
                                      
                      
    
27 
 
                                  
                      
              
 
The likelihood function of the ith subject is the expected conditional likelihood with respect 
to the frailty as shown, where       is the probability density function of the Gamma 
distribution of the frailty   
                  ∫                          
  
 
           
 
The full likelihood function is therefore the product of the likelihood function of all subjects 
as presented below 
                 ∏                 
 
   
           
 
Instead of maximizing expression (2.8), a log-transformation is performed to obtain the log-
likelihood function for the ease of parameter estimation as shown 
                      
 ∫ ∑                                                 
 
   
  
 
           
where             and     are the abbreviated form of the conditional probabilities 





2.2.2 Parameter Estimation 
We approximate the log-likelihood function (2.9) using the Gaussian quadrature techniques 
as introduced by Liu and Huang (2008). The basic idea is to estimate the integral of a 
parametric function with regards to a frailty distribution by a weighted sum of the targeted 
function at some pre-specified quadrature points.  More specifically, the integral log-
likelihood function (2.9) is approximated by a weighted sum of the conditional log-likelihood 
functions evaluated at certain pre-defined quadrature points    (q = 1, 2, …, Q) as follow 
                 
 ∑[∑                                          ]      
 
   
 
   
                 
The weight function     , which is defined in a closed interval [     ], has a sequence of 
orthogonal polynomials                    . The polynomial       has q real roots, or 
quadrature points equivalently, between    and    where                 . 
      may then be calculated as a function of        (Golub and Welsch 1969). If the 
frailty   is normally distributed, then    √    and       √         
  . The values of 
   and    may be obtained from tables in the handbook of Abramowits and Stegun (1972).  
 
The procedure for implementing the Gaussian quadrature estimation may be made via SAS 
PROC NLMIXED (SAS 9.2), however, this is currently built for normal frailty only. 
Nevertheless, as recommended by Nelson et al. (2006), we can adopt the probability integral 
transformation method to generate a non-normal random variable by inverting the cumulative 
distribution function (CDF) at values of the standard CDF of a normal random variable. 
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Applied to the Gamma frailty, let   be a standard normal variable with         . Then the 
CDF of  ,    , follows a uniform distribution as           . Likewise, the CDF of a 
Gamma random variable  ,     , also follows a uniform distribution with            . 
Therefore, the Gamma random variable can be generated by an inverse CDF as below 
     (    )                
 
The SAS PROC NLIMXED (SAS 9.2) algorithm allows the users to self-define their own 
conditional log-likelihood functions. For our model, we specify the conditional log-likelihood 
function as the integrand of function (2.9), with Gamma frailties generated through function 
(2.11). The default Gaussian quadrature method in combination with the pre-defined normal 
random effects may then be carried out to estimate the parameters.   
 
2.3 IMPUTING THE UNKNOWN FIRST FAILURE IN THE PRESENCE OF TIES 
Amongst subjects who are diagnosed with tied failures, the parameter estimates obtained via 
the MLE method can then be used to estimate the probability that Event 1 or Event 2 is the 
first failure. 
 
In the presence of tied failures for the ith subject, we first calculate                     , the 
conditional probability of Event 1 occurred first followed by Event 2. This is the scenario as 




                     
 
 
   
    [           ]     [           ]     [              ] 
       [           ]            
where              , and              .  A detailed derivation of this conditional 
likelihood can be found in Appendix 1. 
 
The unconditional probability                     can be further obtained by taking integral 
with respect to the   frailty and is defined as follow 
                    






   
[(
 










]   
 
     
 
 
   
 
     
 
 
             
where                          and             . 
The Laplace transformation for the Gamma distribution allows a closed form for the above 
probability. 
 
Similarly, in the presence of tied failures for the ith subject, we can write the conditional 
likelihood of Event 2 occurred first followed by Event 1 (See Figure 2.5) as follow 





   
    [           ]     [           ]     [              ] 
       [           ]            
where a and b are defined as in expression (2.12). Further details on the derivation can be 
found in Appendix 2. 
 
Its corresponding unconditional likelihood function can be similarly derived as follow 
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]   
 
     
 
 
   
 
     
 
 
             
where             ,     and    are defined as in expression (2.13). 
 
Define pi, the probability of Event 1 being the first failure for the ith subject with tied failures, 
and        , the probability of Event 2 being the first failure, as follow 
   
                   
                                       
                    
We estimate the probability    using the parameters obtained via the MLE method as follow 
 ̂  
      ̂   ̂   ̂   ̂   ̂ 
      ̂   ̂   ̂   ̂   ̂        ̂   ̂   ̂   ̂   ̂ 
            
32 
 
The unknown first failure Ji can thereafter be imputed by a Bernoulli distribution as 
                . The true first failure is Event 1 if      , and Event 2 if     . 
 
A classical competing risks dataset is obtained once all tied first failures have been imputed 
to determine the ‘true’ cause of failure. The standard competing risks methods such as the 
cause-specific hazard regression may then be implemented to assess the effect of the 
covariates of interest.  
 
Extensive simulation studies are carried out in Chapter 3 to evaluate the performance of the 
proposed method in the parameter estimation and the identification of the unknown first 












      Evaluating the Performance of the Proposed Method 
The aims of this chapter are to evaluate the accuracy, efficiency and robustness of the 
proposed method in parameter estimation and identifying the unknown first failures through 
rigorous simulation studies. The data simulation followed the procedure recommended by 
Kim et al. (2010) who generated datasets in survival analysis framework which consisted of 
both right and interval censored failure times. They looked at early breast cancer patients who 
were followed up periodically, and interval censored failure times were recorded for those 
who were diagnosed with breast deterioration. Hence in the simulation, they generated 
interval censoring for subjects who were assumed to have experienced an event (i.e. not right 
censored). Our study extended their methods in the context of multiple failures and we 
generated our simulated dataset as follow: In step 1, we simulated the time to failure for the 
main event, Event 1, and the time to failure for the competing event, Event 2 for each subject. 
The minimum of the two failure times was recorded as the time to first failure, with the other 
being the time to second failure. In steps 2 and 3, we imposed right and interval censoring to 
the failure times. As suggested in section 1.3.1 and 1.7, subjects who experienced at least one 
failure had interval censored failure times. Hence, it is important to generate interval 
censoring after the right censoring is considered. In step 4, those with first and second 
failures in the same time interval were regarded to have experienced tied failures. Extensive 
simulation studies are conducted in section 3.2 by varying rate parameters    and   , 
treatment effects    and   , and variance of the frailty  , and the results are presented in 
Table 3.1 to Table 3.3. In section 3.3, the proposed method was applied to a simulated dataset 
to assess its accuracy in identifying unknown first failures as compared to the JM and WC 
methods. The standard cause-specific hazard regression analysis was subsequently 
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implemented after the ties were broken via each of the three methods. Simulation results in 
relation to the parameter estimation and identification of the unknown cause of failure are 
discussed in section 3.4. 
 
3.1 DATA GENERATION 
Our illustrative dataset based on a randomised trial comprising two regimens of 
chemotherapy in operable paediatric osteosarcoma (Souhami et al. 1997) as described in 
section 1.3.2 can be thought as having both right (patients who did not experience any event 
at study termination) and interval censored (patients who experienced an event between two 
consecutive visits) observations. In addition, multiple failures (either successive failures or 
tied failures) were detected in a subset of the patients. Hence, we will not only simulate a 
competing risks dataset with right censored observations, but also failure time interval for 
each event time. If the failure time intervals of different events from the same subject overlap, 
tied failures are said to have occurred. Otherwise, successive failures would be observed. The 
detailed data generation procedure is given below. 
 
3.1.1 Generation of Event Times 
We simulated a competing risks dataset with tied failures in the framework of a randomised 
controlled clinical trial comparing the efficacy of an experimental treatment versus a placebo.  
First, we generated the treatment variable x from a binomial distribution with a sample size n, 
assuming an equal probability of 0.5 for being allocated the experimental treatment or 
placebo. Thus we had                  . We also assigned a frailty term, , to each 
subject, which was generated from a Gamma distribution with mean 1 and variance  . 
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Assuming the failure time to Event 1 and Event 2 followed an exponential distribution with 
rate parameters    and    respectively, we then simulated the time to Event 1 by 
                           ) and the time to Event 2 by                            ) 
where    and    were the treatment effects for Events 1 and 2 respectively, based on the 
proposed model of equation 2.1. 
 
In the context of multiple failures, a subject was considered to fail from the main event, Event 
1, if the failure time to Event 1 was less than that of Event 2, or in mathematical equivalent 
     . The competing event, Event 2, would then be considered as the second failure as it 
occurred after Event 1, and vice versa if      .  
 
As a result, we denote                , the minimum of    and   , as the time to first 
failure, and                                as the type of first failure. Similarly, we 
define                 and                               as the time and type 
of the second failure respectively. 
 
3.1.2 Generation of Right Censored Observations 
Defining T as the time of study closure, we conventionally assumed that subjects were right 
censored uniformly through the study and generated the right censoring time    by 




If the right censoring time was less than the time of first failure, that was        , the 
subject was assumed not to experience any event and hence was considered right censored. 
However if             , the subject was considered to have experienced first failure, 
either Event 1 or Event 2 only. If the right censoring time was beyond the second failure time, 
that was        , a subject was assumed to have experienced two events, a tied event of 
Events 1 and 2, or Event 1 followed by Event 2, or vice versa. Whether these two events are 
detected simultaneously (i.e. tied failures) or successively (i.e. consecutive failures) is 
dependent on the investigation period, as discussed in the following section. 
 
3.1.3 Generation of Interval Censored Observations 
To generate interval censored failure times, Kim et al. (2010) assumed that patients entered a 
study at different times and the follow-up schedule varied from patient to patient, to reflect 
the practical situation that a trial might not necessarily adhere to the pre-specified follow-up 
schedule for various reasons. We considered a similar procedure in our study. For those who 
had experienced a first failure (i.e.             ), we generated a study enrollment time 
                and an investigation period                  for each subject. The 
failure time,     , was then defined as                            with k = 1, 
2, …as in Kim et al. (2010). The observed failure time interval could be recorded as (TL1, 
TR1) with                  and             . Clinically, TL1 represented 
the time of last follow-up when no failure was detected, and TR1 denoted the time when the 




For subjects who experienced both Events 1 and 2 (i.e.        ), we applied a similar 
procedure for generating interval censoring proposed by Kim et al. (2010) to subsequent 
failure times. Besides the failure time interval for the first event, we further generated the 
interval for the second event by       
                  
      with    
     . If we defined          
         and         
     , the failure time 
interval for the second event could be written as (TL2, TR2), where     was the latest 
follow-up time when a second failure was not observed and     represented the earliest time 
to detect a second failure. 
 
The shorter the failure time interval (or equivalently, the more frequent the follow-up), the 
more accurate our observation for the actual failure time. Conversely, with a wider failure 
time interval (or equivalently, less frequent follow-up), we would expect to lose more 
information on the exact failure time as well as the disease progress. 
 
3.1.4 Generation of Tied Failures 
If the failure time interval of the two events overlapped, or mathematically equivalent 
        and        , the two events were said to have occurred in the same 
investigation interval. Hence, tied failures would be reported on the subject. 
 
The uniform interval (L, R) that was used to generate the investigation period, len, is critical 
for simulating the tied failures. The wider (L, R) is, the longer the investigation period will be. 
Consequently, more consecutive failures will fall into the same investigation interval. This 
results in a greater number of tied failures in the competing risks dataset. 
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3.2 EVALUATING THE PERFORMANCE OF PARAMETER ESTIMATION 
3.2.1 Simulation Settings  
In this section, we assessed the performance of the MLE method as described in section 2.2 
assuming: (1) percentage of ties varying from 10% to 30%; (2) 20% and 30% censoring; and 
(3) different sample sizes (n = 400 and 800). 
 
We considered a simple situation where the failure time distributions of the two events shared 
the same rate parameter, i.e.         and        . We further evaluated the 
parameter estimation assuming three treatment settings: (1)        , or equivalently, 
hazard ratio for Event 1 (HR1) = hazard ratio for Event 2 (HR2) = 1. This represented a 
general situation where there was no treatment effect on the two events; (2)      and 
        , or HR1 = 1 and HR2 = 0.5 equivalently. This represented cases where treatment 
had no effect on the main event, but a beneficial effect on the competing risk; and (3) 
         and       , or equivalently HR1 = 0.5 and HR2 = 2, representing situations 
where treatment had a beneficial effect on main event but an adverse effect on the competing 
risk. The variance of the frailty, , remained constant at 2 throughout simulation studies, as it 
did not have a significant influence on the average hazard rates of Event 1 and Event 2. 
 
Simulation results of each setting were obtained based on 1,000 replications. Statistics 
including bias, standard error (SE), mean square error (MSE) and 95% coverage probability 
(CP) were used to summarise the performance of the MLE method. The bias measures the 
accuracy of an estimator, and SE conveys an estimator’s efficiency. MSE is defined as 
                            . If there are several estimators, we usually not 
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only look at the unbiasness of an estimator, but also its SE. We may hence choose an 
estimator with the smallest MSE, as the summary statistic of bias and SE. The 95% CP 
provides an interval estimate of the accuracy of an estimator. It is calculated as the 
probability that the 95% confidence interval of an estimate covers the true value of a 
parameter amongst 1,000 replications. The detailed SAS codes on the data generation and 
parameter estimation can be found in Appendix 3. 
 
3.2.2 Simulation Results 
3.2.2.1 Performance of Proposed Method Assuming Different Percentages of Ties 
Table 3.1 presents the simulation results with percentage of ties varying from 10% to 30%, 
assuming a sample size of 400 and 20% censoring. We fixed parameters         and 
   . The study termination time was set to be 10, 10 and 8 respectively for the three 
treatment settings to ensure 20% right censoring. For the first treatment setting, the uniform 
interval (L, R) was chosen to be (0.08, 0.16), (0.2, 0.3) and (0.3, 0.6) corresponding to 10%, 
20% and 30% ties respectively. The interval length was later increased to (0.1, 0.2), (0.2, 0.4) 
and (0.4, 0.7) for the second treatment setting, because the adverse effect of treatment,   , 
reduced the overall hazard rate of Event 2. The last treatment setting adopted the same 
intervals as those for the second treatment setting as we assumed similar adverse effect of 






Table 3.1 Simulation Results Assuming Varying Percentages of Ties from 10% to 30%, HR = 0.5, 1 or 2, Constant            , n 
= 400 and 20% Censoring 
 HR1 = HR2 = 1 HR1 = 1, HR2 = 0.5 HR1 = 0.5, HR2 = 2 
 BIAS SE MSE CP (%) BIAS SE MSE CP (%) BIAS SE MSE CP (%) 
10% tie             
   0.037 0.348 0.123 95.4 0.017 0.345 0.119 94.7 0.021 0.360 0.130 93.4 
   0.038 0.339 0.116 95.9 0.015 0.335 0.112 94.2 0.014 0.355 0.126 94.0 
   -0.019 0.234 0.055 95.5 0.002 0.224 0.050 95.6 -0.021 0.252 0.064 95.2 
   -0.020 0.229 0.053 95.1 -0.005 0.235 0.055 95.4 -0.008 0.233 0.055 94.5 
  0.004 0.170 0.029 96.4 -0.011 0.185 0.034 93.8 -0.011 0.189 0.036 93.6 
20% tie             
   -0.002 0.353 0.125 93.2 0.007 0.352 0.124 93.7 0.005 0.355 0.126 94.1 
   0.002 0.338 0.114 93.7 0.012 0.357 0.127 93.1 0.010 0.360 0.130 92.9 
   -0.004 0.235 0.055 94.3 0.012 0.233 0.055 95.2 -0.005 0.244 0.059 94.9 
   -0.010 0.230 0.053 95.3 0.001 0.239 0.057 94.8 0.003 0.238 0.056 95.6 
  -0.005 0.187 0.035 94.6 -0.005 0.187 0.035 94.7 -0.011 0.192 0.037 93.8 
30% tie             
   <0.001 0.355 0.126 93.3 -0.010 0.370 0.137 92.7 -0.046 0.364 0.135 92.4 
   0.004 0.367 0.134 93.0 -0.022 0.357 0.128 93.1 -0.046 0.367 0.137 91.7 
   -0.012 0.233 0.054 95.2 -0.005 0.240 0.057 94.4 -0.001 0.251 0.063 93.9 
   -0.013 0.241 0.058 94.6 -0.003 0.242 0.058 94.9 -0.001 0.256 0.065 95.3 
  -0.017 0.186 0.035 94.6 -0.021 0.202 0.041 92.9 -0.041 0.200 0.042 93.3 
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Table 3.1 shows that as the percentage of ties increased, the bias of    and    appeared to 
decrease first and then increase. For example as the ties increased from 10% to 20%, the bias 
of    and    reduced from 0.017 and 0.015 to 0.007 and 0.012 for HR1 = 1 and HR2 = 0.5, 
and from 0.021 and 0.014 to 0.005 and 0.010 for HR1 = 0.5 and HR2 = 2. As ties increased 
further to 30%, the bias of     and    rose to -0.010 and -0.022 for the first setting, and -0.046 
and -0.046 for the latter setting. The bias of   generally increased with the increasing number 
of ties. For example for HR1 = HR2 =1, the bias of   increased from 0.004 to -0.017 with 
proportion of ties increasing from 10% to 30%. The simulation results, however, did not 
seem to suggest any particular pattern between the bias of    and    and the proportion of 
tied failures. 
 
Generally, the SE increased with the percentage of ties. For HR1 = HR2 = 1 for 
example,     ) rose from 0.348 to 0.355 for percentage of ties ranging between 10% and 
30%. Likewise,        increased gradually from 0.355 to 0.367 for HR1 = 0.5 and HR2 = 2, 
as the percentage of ties increased from 10% to 30%.  Similar trends were found for       , 
       and      . 
 
There were slight changes in MSE across three treatment settings with ties increased from 10% 
to 20%. For example, the MSEs of the five parameters were 0.123, 0.116, 0.055, 0.053 and 
0.029 with 10% ties and 0.125, 0.114, 0.055, 0.053 and 0.035 with 20% ties for HR1 = HR2 = 
1. For HR1 = 0.5 and HR2 = 2, the MSEs changed from 0.130, 0.126, 0.064, 0.055 and 0.036 
to 0.126, 0.130, 0.059, 0.056 and 0.037. The increment in MSE seemed more substantial as 
ties reached to 30%. For instance,        increased from 0.114 to 0.134 for HR1 = HR2 = 1, 
and        changed from 0.056 to 0.065 for HR1 = 0.5 and HR2 = 2. 
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The 95% CPs of    and    tended to decline as the number of tied failures increased. For HR1 
= HR2 = 1, the 95% CPs were close to 95% under 10% tie. They declined to about 93% when 
the percentage of ties was at least 20%. Similar results were found for HR1 = 1 and HR2 = 0.5, 
and HR1 = 0.5 and HR2 = 2. The 95% CPs of    and    were relatively stable as compared to 
   and   . They remained close to 95% under different proportions of ties for varying HRs. 
The 95% CP of   was the most stable with a coverage of about 94% for all treatment settings 
regardless of percentages of ties. 
 
3.2.2.2 Performance of Proposed Method Assuming Different Percentages of Censoring 
Table 3.2 reports the results of simulation under various percentages of right censoring 
assuming a sample size of 400 and 10% tie. We set         and    . The uniform 
interval (L, R) was set to be (0.1, 0.3), (0.2, 0.4), and (0.2, 0.4) to generate 10% tie for the 
three treatment settings respectively. We let T = 20 to allow 20% censoring and 8 for 30% 
censoring for the first treatment setting. The second treatment setting used the same values of 
T to produce the corresponding percentages of censoring. T was reduced to 16 and 6 for the 
third treatment setting. 
 
Table 3.2 shows a positive relationship between the bias and the percentage of censoring. As 
the percentage of censoring increased from 20% to 30%, the bias of the five parameters 
generally increased, but only by a very marginal amount. For example, for HR1 = HR2 = 1, 
the bias of             and   was 0.002, 0.003, 0.003, 0.010 and -0.009 under 20% 




Table 3.2 Simulation Results Assuming Varying Percentages of Censoring from 20% to 30%, HR = 0.5, 1 or 2, Constant       
     , n = 400 and 10% Ties 
 HR1 = HR2 = 1 HR1 = 1, HR2 = 0.5 HR1 = 0.5, HR2 = 2 
 BIAS SE MSE CP (%) BIAS SE MSE CP (%) BIAS SE MSE CP (%) 
20% 
censoring 
            
   0.002 0.179 0.032 93.0 0.002 0.164 0.027 95.0 0.003 0.169 0.029 94.3 
   0.003 0.175 0.031 93.4 0.003 0.178 0.031 93.3 0.004 0.169 0.029 93.7 
   0.003 0.238 0.056 94.6 -0.003 0.229 0.052 94.7 -0.019 0.258 0.067 95.0 
   0.010 0.231 0.053 95.8 0.001 0.254 0.064 94.2 -0.005 0.231 0.053 94.3 
  -0.009 0.177 0.031 95.2 -0.011 0.187 0.035 94.4 -0.007 0.186 0.035 95.1 
30% 
censoring 
            
   -0.002 0.183 0.034 93.2 0.004 0.165 0.027 95.4 0.008 0.177 0.031 93.7 
   -0.007 0.179 0.032 92.3 -0.004 0.174 0.030 94.6 0.004 0.179 0.032 93.0 
   0.003 0.246 0.061 94.7 -0.002 0.223 0.050 96.2 -0.013 0.271 0.073 94.1 
   0.013 0.249 0.062 93.3 0.003 0.249 0.062 94.2 -0.019 0.241 0.058 94.2 
  -0.017 0.209 0.044 94.4 -0.013 0.213 0.045 95.3 -0.01 0.218 0.048 95.0 
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The SE of the estimates also generally increased with the corresponding increase in the 
proportion of right censoring for most settings. For example for HR1 = HR2 = 1, the SEs of 
the five parameters             and   were 0.179, 0.175, 0.238, 0.231 and 0.177 under 20% 
censoring. With 30% censoring, the SEs increased to 0.183, 0.179, 0.246, 0.249 and 0.209.  
 
The MSE was generally larger under 30% censoring as compared to 20% censoring, 
especially for HR1 = HR2 = 1 and HR1 = 0.5 and HR2 = 2.  For example, for HR1 = HR2 = 1, 
the MSEs for the five parameters             and   changed from 0.032, 0.031, 0.056, 0.053 
and 0.031 to 0.034, 0.032, 0.061, 0.062 and 0.044 respectively. Moreover, the MSEs shifted 
from 0.029, 0.29, 0.067, 0.053 and 0.035 to 0.031, 0.032, 0.073, 0.058 and 0.048 for HR1 = 
0.5 and HR2 = 2. However, the increment in MSEs for HR1 = 1 and HR2 = 0.5 were less 
notable. 
 
The 95% CPs of    and    declined slightly as the percentage of censoring increased, but 
remained at least 93%. The 95% CPs of       and   appeared relatively stable and remained 
close to 95% regardless of the censoring percentages. 
 
3.2.2.3 Performance of Proposed Method Assuming Different Sample Sizes 
Table 3.3 assumes the same simulation scenario as Table 3.2 under 10% tie and 20% 





Table 3.3 Simulation Results Assuming HR = 0.5, 1 or 2, Constant            , n = 800, 10% Ties and 20% Censoring 
 HR1 = HR2 = 1 HR1 = 1, HR2 = 0.5 HR1 = 0.5, HR2 = 2 
 BIAS SE MSE CP (%) BIAS SE MSE CP (%) BIAS SE MSE CP (%) 
   0.005 0.123 0.015 95.1 0.009 0.118 0.014 94.6 <0.001 0.120 0.014 94.1 
   0.002 0.125 0.016 94.9 0.005 0.120 0.014 93.9 0.001 0.118 0.014 95.2 
   -0.002 0.165 0.027 95.2 -0.001 0.157 0.025 94.9 -0.004 0.181 0.033 94.4 
   0.003 0.163 0.027 95.1 0.001 0.166 0.027 96.1 -0.001 0.167 0.028 94.6 










In general, as the sample size increased from 400 to 800, there was a significant reduction in 
bias of the estimates. For example for HR1 = 0.5 and HR2 = 2, the bias of    and    reduced 
to <0.001 and 0.001 for n = 800, as compared to bias of 0.003 and 0.004 for n = 400. More 
significantly, the bias for    and    went down from -0.019 and -0.005 to -0.004 and -0.001 
respectively with a double-fold increase in sample size. The bias of   also declined from -
0.009 to -0.001 for HR1 = HR2 = 1 and from -0.011 to 0.001 for HR1 = 1 and HR2 =0.5. 
 
The SE also decreased appreciably as the sample size was doubled. For HR1 = 1 and HR2 = 
0.5 for example, the SEs of              and   were 0.164, 0.178, 0.229, 0.254 and 0.187 for 
n = 400, but they reduced to 0.118, 0.120, 0.157, 0.166 and 0.130 when n = 800.  
 
The MSE was almost halved as a result of reduction in both bias and SE. As shown for HR1 = 
HR2 = 1, the respective MSE for the five parameters were 0.032, 0.31, 0.056, 0.053 and 0.031 
for n = 400 and they reduced to 0.015, 0.016, 0.027, 0.027 and 0.017 for n = 800. Similar 
patterns were observed for HR1 = 1 and HR2 = 0.5, and HR1 = 0.5 and HR2 = 2. 
 
The 95% CP was almost achieved in most instances as the sample sizes increased. For 
example, for both    and   , it increased from 93% for n = 400 to 95% for n = 800 for HR1 = 





3.3 PERFORMANCE OF PROPOSED METHOD IN IDENTIFYING THE 
UNKNOWN FIRST FAILURE 
We assessed the accuracy of the proposed SF method in identifying the unknown first failures 
by comparing it to the WC and JM methods both of which assume random allocation of first 
failures in ties.  
 
We first simulated a competing risks dataset with right and interval censored failure times 
following the procedure described in section 3.1.1 to 3.1.3. We considered a dataset of 400 
with parameters      and     . The hazard rate of main Event 1 was assumed to be 
twice that of the competing Event 2 to avoid having the same number of Event 1 and Event 2 
first failures in the subsequent generation of ties. We further investigated the simplest 
situation where treatment had no effect on both events, i.e.        . We fixed the 
variance of the frailty at    , study termination time     and assumed (L, R) to be 
Uniform (0.4, 0.7). These yielded 24.3% right censoring. At this stage, we have not 
considered tied failures and all first failures were known. According to follow-up practice, 
the latest visit time is often recorded as the best estimate of the true failure time if a failure 
has occurred, and so we directly implemented the cause-specific hazard regression analysis to 
study the treatment effects for Events 1 and 2 in this instance when no tied failure was 
assumed. The number of first failures in the two treatment groups, estimated treatment effects 
and their SEs are presented in Table 3.4 under the category of ‘True first failures known’. 
 
We further generated tied failures by implementing an additional step in section 3.1.4, and 
the simulation setting described above yielded 22.5% ties. Assuming the actual first failures 
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were unknown in the presence of ties, we thus applied the SF, WC and JM methods to break 
the ties respectively. After the unknown first failures were identified by each of the three 
methods, we conducted the cause-specific hazard regression analysis subsequently to 
evaluate the treatment effect. To circumvent possible uncertainty or randomness due to single 
imputation, we adopted the multiple imputation procedure of Rubin and Schenker (1991) 
assuming 300 replications for both the SF and JM methods. The results are provided in Table 
3.4. The SAS and STATA codes for analysing the simulated data using different methods can 
be found in Appendix 4.     
 
Table 3.4 shows that in the event of tied first failures, the SF method gave an estimated 
probability that was much closer to the true probability of Event 1 being the first failure in 
ties (58.0% versus 63.3%), as compared to the WC and JM which assumes 50% probability 
of failing from Event 1. 
 
In the handling of ties, the WC and JM underestimated the number of Event 1 failure and 
overestimated the number of Event 2 failure in both treatment groups. The differences in the 
total number of events for the two events were substantial (204.0 versus 192.0 and 192.2 for 
Event 1 and 99.0 versus 110.0 and 110.8 for Event 2). On contrary, the SF method effectively 
reduced the bias in the estimated number of events, and resulted in improved estimates of the 






Table 3.4 Estimated Number of Events and Treatment Effect Based on SF, WC and JM 
methods assuming HR1 = HR2 = 1, Constant              , n = 400,  22.5% ties 
and 24.3% censoring 
Method P
a
  Number of events
b 
logHR SE 








Event 1       
True first failures known 63.3% 97.0 107.0 204.0 -0.071 0.140 
SF 58.0% 91.4 107.8 199.2 -0.003 0.142 
WC 50.0% 88.0 104.0 192.0 -0.001 0.136
c 
JM 50.2% 88.1 104.1 192.2 -0.002 0.145 
Event 2       
True first failures known  46.0 53.0 99.0 -0.022 0.202 
SF  51.6 52.2 103.8 -0.155 0.197 
WC  55.0 56.0 110.0 -0.148 0.169
c 
JM  54.9 55.9 110.8 -0.147 0.190 
a. Denotes the actual percentage of Event 1 first failures among the ties when all true first 
failures are known, the average percentage of Event 1 first failures among the ties from 300 
replications after the ties are broken for SF and JM, and weight for Event 1 as the first failure 
in a tie for WC. 
b. Denotes the average number of events from 300 replications after the ties are broken for 
SF and JM, and weighted number of events for WC. 
c. Denotes robust SEs adjusted for the clustering effect for WC. 
 
Generally, the three methods gave similar estimates of treatment effect for Event 1 (-0.003, -
0.001 and -0.002) and Event 2 (-0.155, -0.148 and -0.147). In evaluating the variability of the 
estimates, the SF method produced SE which was the closest to the real SE for the respective 
events. The WC tended to underestimate the variability of the estimates, while the JM 




We propose a SF model in handling tied failures in competing risks analysis. The SF model 
utilises existing information of distinct failures and interval censored failure times to identify 
unknown first failures, and thus the subsequent cause-specific hazard regression analysis may 
be implemented more satisfactorily. 
 
We conducted simulation studies in a wide range of scenarios to test the performance of the 
proposed method with respect to the bias, SE, MSE and 95% CP. In general, the results show 
that the bias, SE and MSE of the estimates increased and CP appeared to deviate slightly 
from 95% for all three treatment settings, as the proportion of ties increased from 10% to 30% 
and censoring rose from 20% to 30% (Tables 3.1 and 3.2). On the other hand, as the sample 
size increased, the bias, SE and MSE of the estimates demonstrated remarkable reduction and 
CP was closer to 95% regardless of the treatment settings (Table 3.3).  
 
As the investigation periods get longer, we are expected to observe more tied failures because 
consecutive failures are more likely to be detected simultaneously in the same investigation 
intervals. Moreover as suggested in section 3.1.3, the information carried by the intervals 
becomes less accurate in determining the actual failure times. This probably explains why as 
the percentage of ties increased, the estimation accuracy (i.e. bias and CP) and efficiency (i.e. 
SE) generally decreased for all treatment settings.  
 
Similarly with increased percentage of right censored observations, the model parameters 
would be estimated based on fewer failures. As a result, we obtained larger bias, SE, MSE 
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and more dispersed CP for all treatment settings. The simulation results again confirmed that 
as compared to the rest parameters,     and    were more sensitive to the loss of information 
due to either interval or right censoring. 
 
Contrary to censoring, information (particularly the information on subjects who have 
experienced at least one failure) accumulates faster as the sample size increases. This could 
be the reason why we observed much smaller bias, SE, MSE and CP closer to 95% in three 
treatment settings as presented in Table 3.3. 
 
We also applied the SF model to a simulated data and evaluated its accuracy in identifying 
unknown first failures. The results show that the SF method gave estimated number of first 
failures and SE of the treatment effect closer to their true values than the WC and JM 
methods (Table 3.4).   
 
The SF model takes into account the information on distinct failures, and utilise this 
information to re-allocate the tied failures to become distinct failures. When the ties are 
substantial, the chance of finding an Event 1 first failure would be higher than Event 2 if 
correspondingly we observe a higher number of distinct first failure in Event 1 as compared 
to Event 2. This may be the reason why the SF method improved the estimation of the 




The SF method generally produced similar estimated treatment effects as the WC and JM 
methods. The deviation from true values is possibly due to the relatively long investigation 
period. As mentioned in section 3.1.3, the failure time interval tends to capture the disease 
progress less precisely if the investigation period gets longer. This possibly explains the 
difference between the estimated probability and the true probability of Event 1 being the 
first failure in ties, which leads to discrepant estimated treatment effects. Nevertheless, the SF 
method generated SEs what were closest to the true values, and thus supported the use of the 
SF method as more information was involved in tackling of tied failures.  
 
To summarise, the simulation studies generally revealed very small bias, acceptable SE and 
MSE. The CP was close to 95%. Hence, the parameter estimation of the SF model 
demonstrated reasonable accuracy, efficiency and robustness when applied to wide variety of 
settings. The SF method also improved the accuracy of identifying the true cause of first 
failure in the event of ties and provided more efficient estimates of SEs for the covariate 
effect. However, the evaluation of treatment effect might be sensitive to the length of 
investigation period, as the estimated treatment effect tended to differ from its true value 









      Application to the Osteosarcoma Clinical Trial Dataset 
In this chapter, we apply the SF model for handling tied failures in competing risks analysis 
to the data from a randomised clinical trial of paediatrics with osteosarcoma (Souhami et al. 
1997). A detailed description of the data is given in section 4.1. We evaluated the treatment 
effect of a multi-drug (MD) regimen of chemotherapy versus a double-drug (DD) regimen in 
relation to the time to development of lung-metastasis and non lung-metastasis, after tied 
failures have been dealt with using the proposed method.  The results were compared to those 
obtained via the WC and JM methods, both of which assume equal allocation of tied failures 
in breaking of the ties. The results based on different approaches are presented in Table 4.2. 
Section 4.3 discusses some issues raised from the data analysis in section 4.2. 
 
4.1 DATA DESCRIPTION 
 The European Osteosarcoma Intergroup conducted a randomised multicenter trial to 
compare two regimens of chemotherapy in operable non-metastatic limb sarcoma: a short 
intensive DD regimen comprising doxorubicin and cisplatin versus a complex and long 
duration MD regimen consisting of vincristine, high-dose methotrexate, bleomycin, 
cyclophosphamide and dactinomycin, in addition to doxorubicin and cisplatin (Souhami et 
al.1997). The primary hypothesis was that the DD regimen would produce equivalent 
survival to the MD regimen. It was also of interest to compare the progression-free-survival 
in the two regimens where disease progression was defined as local recurrence and metastasis 




A total of 407 patients were randomised to the two treatment groups. Surgery was planned for 
week nine, three weeks after three cycles of chemotherapy for the DD group, and week seven, 
a week after the fourth course of high-dose methotrexate for the MD group. After the surgery, 
the patients would enjoy a disease-free period, and might subsequently experience relapses as 
defined above. Patients who completed the treatment were scheduled to be assessed by chest 
radiography every three weeks for the first six month, every six weeks for months 6-18, every 
two months during months 18-36, every three months in years 3-5 and annually thereafter.   
 
We excluded five patients from our data analysis. These included four patients from whom 
no further information was available after the randomisation, and one patient who died of 
treatment-related causes. This patient was excluded because we were not able to analyse the 
sole observation of this single event category. Thus, in total, 402 patients were included in the 
data analysis, with 202 patients assigned to receive DD and 200 allocated to receive MD. 
 
A detailed summary on the site of first failures before ties were broken can be found in Tai et 
al. (2002). Four main types of relapses were diagnosed in these patients: local recurrence, 
lung metastasis, bone metastasis and other metastasis. Tai et al. (2002) grouped them into 
three categories: local recurrence, lung metastasis and other metastasis including bone and 
other metastases. Without loss of generality, we re-classified the type of relapses into lung- 
and non lung-metastasis for simplicity in order to apply our proposed model. As shown by 
Tai et al. (2002), the lung metastasis (38.1%) was the predominant cause of failure as 
compared to local recurrence (4.2%) and other metastasis (4.4%). In an earlier study, Tai et al. 
(2001) demonstrated that the cumulative incidence of lung metastasis was almost fourfolds 
that of local recurrence and other metastasis. On the other hand, local recurrence and other 
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metastasis shared very similar number of events as well as cumulative incidence. We 
summarise the data involving the two-event categories in Table 4.1.  
Table 4.1 Site of First Failure before Tied Failures were Broken (Data from Souhami et 
al. 1997) 
Site of first failure DD MD Total 
 N (%) N (%) N (%) 
No event 92 (45.5) 86 (43.0) 178 (44.3) 
Lung-metastasis 75 (37.1) 78 (39.0) 153 (38.1) 
Non lung-metastasis 15 (7.4) 20 (10.0) 35 (8.6) 
Tied failures 20 (10.0) 16 (8.0) 36 (9.0) 
 
 
4.2 DATA ANALYSIS 
We compare the results obtained from SF with those of WC and JM methods proposed by Tai 
et al. (2002), and present them in Table 4.2. The SAS and STATA codes for analysing the 
osteosarcoma data can be found in Appendix 5. 
 
Based on the SF method, lung-metastasis was estimated to have occurred first in the event of 
tied failures with a probability of 51.1%. This suggested that lung-metastasis and non lung-
metastasis were almost as likely to happen first in patients who were diagnosed to have failed 
from both causes simultaneously. 
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Table 4.2 Estimated Number of Events and Treatment Effect Obtained Based on SF, 
WC and JM methods (Data from Souhami et al. 1997) 
Model p
a
  Number of events
b 
logHR SE 
  DD MD Total MD versus DD  
Lung- metastasis       
SF 51.1% 85.2 86.2 171.4 0.029 0.153 
WC 50.0% 85.0 86.0 171.0 0.030 0.149
c 
JM 50.6% 85.2 86.0 171.2 0.028 0.153 
Non lung-metastasis       
SF  24.8 27.9 52.6 0.137 0.277 
WC  25.0 28.0 53.0 0.131 0.250
c 
JM  24.8 28.0 52.8 0.138 0.277 
a. Denotes the average percentage of Event 1 first failures among the ties from 300 
replications after the ties are broken for SF and JM, and weight for Event 1 as the first failure 
in a tie for WC. 
b. Denotes the average number of events from 300 replications after the ties are broken for 
JM and SF method, and weighted number of events for WC. 
c. Denotes robust SEs adjusted for the clustering effect for WC. 
 
 
As this estimate was similar in probability to those of WC and JM methods, both of which 
assume random allocation of tied events, we thus obtained similar estimates for the number 
of events and treatment effect for all methods. The SEs obtained from SF were very close to 







We illustrate the application of the proposed SF model using the data from a randomised 
clinical trial on paediatric osteosarcoma (Souhami et al. 1997). The SF method produced 51.1% 
average percentage of lung-metastasis  as the first failure in the presence of ties, thus yielding 
similar estimated number of events and treatment effects for the two events as the WC and 
JM methods. The SEs generated by SF and JM methods were relatively close, but those of the 
WC methods were comparatively smaller. The results were consistent with the findings of 
Tai et al. (2002) who suggested that the WC method does not consider the order of tied 
failures and hence results in less randomness in the estimation of treatment effect. 
 
The results of the SF method suggested that lung- and non lung-metastasis were almost 
equally likely to occur first in the event of ties. This is possibly due to the limited number of 
ties. When the number of tied failures is much smaller than that of distinct failures (for the 
osteosarcoma data, 36 versus 188), the chance of observing lung-metastasis as the first failure 
in ties would be lower than that in distinct failures. This could be one possible reason why we 
obtained a smaller estimated proportion of lung-metastasis in ties as compared to distinct 
failures.  
 
To conclude, our results supported the findings of Souhami et al. (1997) and Tai et al. (2002) 
that there was no significant difference in the treatment effect between the DD and MD 
regimens in relation to the time to development of lung-metastasis and non lung-metastasis. 
Hence, the DD regimen should be the preferred treatment due to its shorter duration and 




      Discussion and Concluding Remarks 
In a competing risks framework where a subject is exposed to more than one cause of failure, 
multiple or tied ‘first’ failures may be detected simultaneously at a particular follow-up. This 
is often observed in cancer clinical trials in which patients are usually investigated 
periodically. Consecutive failures are likely to be detected at the same visit if the 
investigation period is relatively long or the follow-up is less frequent. If the tied failures are 
substantial, standard competing risks analysis methods such as cause-specific hazard 
regression may not be applied satisfactorily as considerable information is missing due to 
unknown cause of failure. In this study, we developed a SF model to identify the true cause 
of failure in the event of ties by taking into account information on distinct failures and the 
dependence between multiple failures arising from the same subject. We conducted extensive 
simulation studies to evaluate the performance of the proposed method with regards to the 
parameter estimation and the identification of unknown cause of failure. Simulation results 
show that the SF method effectively improved the accuracy of identifying the unknown cause 
of failure and the robustness in estimating covariate effect. However, the estimation of 
covariate effect was sensitive to the length of the investigation period. The SF method was 
further applied to the data from a randomised clinical trial of paediatrics with osteosarcoma 
(Souhami et al. 1997) to evaluate the treatment effect of a DD regimen of chemotherapy 
versus a MD regimen in association with the time to development of lung-metastasis and non 
lung-metastasis. The results were compared with those obtained via the WC and JM methods 
proposed by Tai et al. (2002), both of which assume random allocation of tied events. The 
results show that the SF method generally produced similar estimated number of events, 
treatment effects and SEs as compared to the WC and JM methods. 
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Although many clinical studies (Klein et al. 1989, Arriagada et al. 1992, Kriege et al. 2008, 
Subotic et al. 2009, Chang et al. 2011 and Sasako et al. 2011) have reported different extents 
of tied failures, none of them has addressed this issue adequately in the analysis of competing 
risks endpoints. Klein et al. (1989), Arriagada et al. (1992) and Kriege et al. (2008) treated 
tied failures as a new category, while Chang et al. (2011) combined ties with a distinct failure 
which was their main research interest. Subotic et al. (2009) and Sasako et al. (2011), 
however, did not provide any explanation on how tied failures were handled in their analyses. 
Tai et al. (2002) were the first who systematically discussed the problem of tied failures in 
the analysis of data from an osteosarcoma clinical trial where the amount of ties was 
substantial. They proposed two methods in tackling ties in competing risks analysis. The WC 
method assigns a weight to each event. A tied event is allocated a weight equal to the 
reciprocal of the number of tied events, whereas a distinct event is assigned a weight of one. 
The weighted Cox regression is then implemented using STATA with a specification of a 
non-integer weighting factor. Correlation between multiple observations from the same 
subject is adjusted by using the default sandwich variance estimator. It is a modified version 
of the robust variance estimator, with additional weights denoting the contribution of each 
cluster to the overall likelihood function. The JM, on the other hand, forces an order for tied 
events by arbitrarily adding or subtracting a very small number to the failure time. A multiple 
imputation procedure is integrated to reduce the randomness raised from single imputation. 
The WC and JM methods are straightforward and easy to implement. However, the equal 
allocation assumption between tied events may not always be valid, especially for diseases in 
which patients are more susceptible to certain type of failure than the others. These two 
methods were discussed in the context of right censoring, which may not reflect the true 
mechanism of the formation of tied first failures in the presence of relapses. Lastly, JM 
method does not consider the dependence arising from multiple observations of a subject, 
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while WC method fundamentally assumes that each subject contributes the same weight to 
the overall likelihood function which may be too strong for most clinical trials that involve 
human subjects. 
 
Compared to the WC and JM methods, the proposed SF method does not assume random 
allocation of tied events. Instead, it makes use of information on distinct failures to break the 
ties. This means that if the proportion of distinct failures in Event 1 is higher than that of 
Event 2, we would generally have a higher chance to observe Event 1 failures than Event 2 in 
the midst of ties, and likewise for Event 2. The simulation study in section 3.3 shows that the 
main Event 1 was the predominant failure amongst those who have experienced distinct 
failures, and the actual percentage of Event 1 failures in ties was distinctly higher than that of 
Event 2. The equal allocation assumption was violated under such circumstance but the SF 
method managed to produce an estimated percentage that was closer to the actual percentage 
of Event 1 in ties (Table 3.4).  Moreover, the SF model captures the dependence between 
failures arising from the same subject using a frailty following a Gamma distribution. The 
frailty model is theoretically more flexible in modelling dependence between different 
failures than the weighted method of WC, as it could take on a variety of distributions. 
Among them, the Gamma frailty gives a simple close form for the probability which could be 
used to impute unknown first failures. Hence, the SF model demonstrated is more accurate in 
identifying the unknown cause of failure and is also more robust in estimating the treatment 
effect as compared to the WC and JM methods (Table 3.4).  
 
Notwithstanding the advantages mentioned above, the SF model also has some potential 
limitations. As discussed in section 3.4, the model is relatively sensitive to the length of the 
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investigation period in estimating the treatment effect. If the investigation period is 
comparatively long or the follow-up is less frequent, the failure time interval is less likely to 
capture the disease progress very precisely. Under this scenario, the SF model did not seem to 
improve the estimation of the treatment effect as much as the estimation of the probability, 
number of events and SE of the treatment effect (Table 3.4). 
 
Our model assumes an exponential distribution for the failure time of the respective events, 
which means the hazard rate is constant over time. This might not always be plausible in 
biomedical data where diseases are wide-ranged and failure time patterns far more complex. 
To allow for a broader application of the proposed method, we may extend the exponential 
distribution to Weibull distribution as it has been used frequently in human mortality studies 
to model failure time with decreasing, increasing or constant hazard. Studies have also 
suggested that the log-normal distribution could well model failure time of several diseases 
such as Hodgkin’s disease and chronic leukemia because it is markedly right skewed and the 
logarithm of the failure time follows an approximately normal distribution (Lee and Wang 
2003). Spline methods may be another parametric alternative for modelling the baseline 
hazard. Various spline methods to estimate the baseline hazard by using the Cox proportional 
hazard model have been proposed (Anderson and Senthilselvan 1980, Kooperberge et al. 
1995, Rosenberge 1995 and Boucher and Kerber 2001).  In a study assessing differences 
between subtype B strain and subtype E strain transmission in relation to human 
immunodeficiency virus type 1 infection, Hudgens et al. (2002) adopted cubic-basis splines 
to estimate the baseline hazard of each subtype assuming an additive hazard model without 
any covariate. Besides the spline methods, the piecewise exponential distribution is also 
popular because of its sufficient robustness in most applications (Lawless and Zhan 1998, 
Chen and Cook 2009). Lawless and Zhan (1998), Feng et al. (2005) and Andersen et al. 
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(1997) further pointed out that a frailty model with simple piecewise constant baseline hazard 
has advantages over a semi-parametric Cox model with frailty, as it yielded excellent 
estimates for both fixed effects and frailty with a specification of eight to ten intervals. 
Moreover, Gray (1994) and Matsuyama et al. (1998) assumed piecewise constant baseline 
hazard in the analysis of Bayesian frailty models. Though appealing in many of these 
potential extension and applications, the distribution of failure time should still be chosen 
carefully in consideration of the computational capability and efficiency. For example, the 
Weibull distribution allows an explicit close form of the conditional likelihood function. 
However, there is no simple function available for the probability of imputing the unknown 
first failure due to the two additional shape parameters.  Another example would be the 
failure time whose hazard rate is assumed to follow linear splines. There is no simple 
expression for the conditional likelihood function, therefore methods such as Monte Carlo 
integral needs to be implemented in order to optimise the computation. Nevertheless, with 
current advances of intensive computational methods in statistical sciences, more possibilities 
are opened for the use of more comprehensive failure time distributions in solving the tied 
first failure problems. 
 
As with many studies on frailty modelling, the Gamma distribution is chosen mainly for its 
mathematical convenience. The Laplace transformation enables a simple closed form of the 
probability in imputing the unknown cause of failure. However, as it does not have any 
biological bases, it may not fit a patient’s frailty naturally. Other options such as an inverse 
Gaussian distribution by Hougaard (1984) may be explored as it allows a closed expression 
for unconditional survival and hazard functions. The advance development in computer 
technology helps us overcome restriction in computing the integral with respect to the frailty. 
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For example, Liu and Huang (2008) implemented the Gaussian quadrature techniques to 
resolve numerical challenges imposed by the log-normal distribution. 
 
Lastly, the SF model essentially assumes that multiple events arising from the same subject 
share the same frailty.  This assumption is sometimes questionable. For example for the 
osteosarcoma data, for those who had distinct failures, majority failed from lung-metastasis. 
This implies that on average, a subject is more susceptible to lung-metastasis than non lung-
metastasis. Hence, we may consider extending the SF model to a correlated frailty model 
which is more general, and in which the SF model is a special case. The correlated frailty 
model assumes that events from a subject are correlated but not necessarily shared, thus there 
are two frailties, one for each event. If the two frailties are independent, there would not be 
any dependence between failure times. However, if the frailties are correlated and equal, the 
correlated frailty model reduces to the SF model (Wienke 2011). 
 
In conclusion, the proposed SF model for handling tied failures in competing risks analysis 
generally improves the accuracy in identifying the true cause of failure in the presence of ties 
and is more robust in estimating the covariate effect as compared to existing methods. 
However, it is sensitive to the length of the investigation period in estimating the covariate 
effect. The current model may be further improved by adapting more flexible failure time 
distributions such as Weibull, log-normal, piecewise exponential or by using various spline 
estimation. More sophisticated techniques, for example, the Gaussian quadrature, may be 
used to explore frailty distributions other than the Gamma distribution. In the event that 
correlation between failures is of particular interest, the correlated shared frailty model might 
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1. Derivation of the conditional likelihood function that Event 1 occurring first followed by 
Event 2 in the presence of tied failures for the ith subject 
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2. Derivation of the conditional likelihood function that Event 2 occurring first followed by 
Event 1 in the presence of tied failures for the ith subject 
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3. SAS codes for simulation studies 
The codes below are based on the simulation study assuming n = 400, HR1 = HR2 =1, 
             , 10% ties and 20% censoring. 
 
%macro replic; 
%do j=1 %to 1000; /* 1,000 replications */ 
 
* Data simulation for one replication; 
* Generate individual information; 
data one&j; 
do i=1 to 400; /* consider of a sample size of 400*/ 
   id=i; 
   trt=rand('BERN',0.5); 
    
   vn=rand('NORMAL'); 
   p=cdf('NORMAL',vn); 
   if p>.999999 then p=.999999; 
   v2=quantile('GAMMA',p,1/2); 
   v=v2*2; /* v is Gamma distributed with mean 1 and variance 2 */ 
 








t1=rand('EXPO')/(2*exp(0*trt+log(v))); /* lambda1=2, beta1=0 */ 




































len=0.08*rand('UNIFORM')+0.08; /* (L,R)=(0.08, 0.16) */    
 
if t1sta<tc then do; 
do until((t1sta>U0+(k1-1)*len) & (t1sta<=U0+k1*len)); 
   put k1=; 







do until((tc>U0+(k1-1)*len) & (tc<=U0+k1*len)); 
   put k1=; 







if t2nda<tc then do; 
do until((t2nda>U0+(k2-1)*len) & (t2nda<=U0+k2*len)); 
   put k2=; 








do until((tc>U0+(k2-1)*len) & (tc<=U0+k2*len)); 
   put k2=; 












*Overall number of 1st events 
delta0=(tc<=t1sta);  
deltau=((tc>t2nda) and (TL1=TL2)); 
delta1=((tc>t1sta) and (status1sta=1) and (deltau ne 1)); 
delta2=((tc>t1sta) and (status1sta=2) and (deltau ne 1)); 
 
*Overall number of 1st and 2nd events 
delta1to0=((tc>t1sta) and (tc<=t2nda) and (status1sta=1)); 
delta2to0=((tc>t1sta) and (tc<=t2nda) and (status1sta=2)); 
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delta1to2=((tc>t2nda) and (deltau ne 1) and (status1sta=1)); 
delta2to1=((tc>t2nda) and (deltau ne 1) and (status1sta=2)); 
 
delta1u2=((deltau=1) and (status1sta=1)); 







*Parameter estimation with variance theta; 
proc nlmixed data=five&j qpoints=30 noad; 
parms lambda1=2 lambda2=2 beta1=0 beta2=0 theta=2; 








if p>.999999 then p=.999999; 
g2=quantile('GAMMA',p,1/theta); 









array LogL {4} logL1-logL4; /*1:right censored,2:Event1,3:Event2,4:tie */ 
 
do i=1 to 4; 
   logL{i}=0; 
end; 
 
if status=0 then logL1=log(sb*sd); 
if status=1 then logL2=log((sa-sb)*sd); 
if status=2 then logL3=log((sc-sd)*sb); 





model TL1 ~ general(loglik); 
random nu ~ normal(0, 1) subject=id; 




* Create datasets containing estimates from all replic; 
%if &j=1 %then %do; 
    data estimates; 
    set est&j; 






    data estimates; 
    set estimates est&j; 











* Summarize estiamtes; 
%macro results(estimates,para,tv,myout=_out); 
%let para=lambda1 lambda2 beta1 beta2 theta; /* macro variable of 
parameters */ 




       %do i=1 %to 5; 
        %let parai=%scan(&para, &i); 
     %let tvi=%qscan(&tv, &i,%str( )); 
   
        * Extract a dataset containing only the ith parameter, and 
create additional variables; 
           data est1&i; 
           set estimates; 
           if parameter="&parai"; 
           run; 
 
           data est2&i; 
           set est1&i; 
           sqre=(estimate-"&tvi"*1)**2; 
           ind=(abs(estimate-"&tvi"*1)<=1.96*StandardError); 
     count=1; 
           run; 
 
           * Calculate summary statistcs; 
           proc means data=est2&i; 
           var estimate sqre ind count; 
           output out=res1&i mean=m&i mse&i mci&i mc&i std=stdest&i 
stdsqre&i stdci&i stdc&i sum=sumest&i sumsqre&i cn&i sumc&i; 
           run; 
 
           * Calculate bias, se, mse, and cp for the parameter; 
           data res2&i; 
           set res1&i; 
     length parameter $10; 
           parameter="&parai"; 
           bias=m&i-"&tvi"*1; 
           se=stdest&i; 
           mse=mse&i; 
           cp=cn&i/sumc&i; 
           keep parameter bias se mse cp;  
           run; 
         %end; 
          
   data &myout; 
         set 
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   %do i=1 %to 5; 
   res2&i 
   %end; 
         ; 































4. SAS and STATA codes for analysing a simulated dataset 
(i) SAS codes for the dataset with all first failures known 
* Data simulation; 
* Generate individual information; 
data one; 
do i=1 to 400; 
   id=i; 
   trt=rand('BERN',0.5); 
    
   vn=rand('NORMAL'); 
   p=cdf('NORMAL',vn); 
   if p>.999999 then p=.999999; 
   v2=quantile('GAMMA',p,1/2); 
   v=v2*2; /* v is Gamma distributed with mean 1 and variance theta */ 
 













































len=0.3*rand('UNIFORM')+0.4;    
 
if t1sta<tc then do; 
do until((t1sta>U0+(k1-1)*len) & (t1sta<=U0+k1*len)); 
   put k1=; 







do until((tc>U0+(k1-1)*len) & (tc<=U0+k1*len)); 
   put k1=; 







if t2nda<tc then do; 
do until((t2nda>U0+(k2-1)*len) & (t2nda<=U0+k2*len)); 
   put k2=; 








do until((tc>U0+(k2-1)*len) & (tc<=U0+k2*len)); 
   put k2=; 






dm 'clear log'; 
run; 
 





delta1=((tc>t1sta) and (status1sta=1)); 





* Evaluate the treatment effect by Cox proportional hazard function; 
proc phreg data=five; 
model TR1*status(0,2)=trt; 
ods output ParameterEstimates=event1; 
run; 
 




ods output ParameterEstimates=event2; 
run;  
 
* Count the number of event 1 and event 2; 
proc means data=five(where=(trt=0)); 
var delta1 delta2; 
output out=nevents0 sum=sum01 sum02; 
run; 
 
proc means data=five(where=(trt=1)); 
var delta1 delta2; 









deltau=((tc>t2nda) and (TL1=TL2)); 
delta1=((tc>t1sta) and (status1sta=1) and (deltau ne 1)); 
delta2=((tc>t1sta) and (status1sta=2) and (deltau ne 1)); 
 
delta1u2=((deltau=1) and (status1sta=1)); 








proc means data=seven; 
var delta1u2; 




(ii) SAS codes for the SF method 





deltau=((tc>t2nda) and (TL1=TL2)); 
delta1=((tc>t1sta) and (status1sta=1) and (deltau ne 1)); 
delta2=((tc>t1sta) and (status1sta=2) and (deltau ne 1)); 
 
delta1u2=((deltau=1) and (status1sta=1)); 





* Parameter estimation; 
proc nlmixed data=newone qpoints=30 noad; 
parms lambda1=2 lambda2=1 beta1=0 beta2=0 theta=2; 
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if p>.999999 then p=.999999; 
g2=quantile('GAMMA',p,1/theta); 









array LogL {4} logL1-logL4; /*1-censored, 2-Event1, 3-Event2, 4-tied */ 
 
do i=1 to 4; 
   logL{i}=0; 
end; 
 
if status=0 then logL1=log(sb*sd); 
if status=1 then logL2=log((sa-sb)*sd); 
if status=2 then logL3=log((sc-sd)*sb); 





model TR1 ~ general(loglik); 
random nu ~ normal(0, 1) subject=id; 






%do j = 1 %to 300; 
 
 
*Extract subjects without tied failures; 
data newtwo&j; 
set newone; 
if status ne 3; 
keep id status trt TL1 TR1; 
run; 
 















































keep id status trt TL1 TR1; 
run; 
 
*Combine subjects without ties and those those with imputed first failures; 





*Evaluate the treatment effect by Cox proportional hazard function; 
proc phreg data=newtwo&j; 
model TR1*status(0,2)=trt; 
ods output ParameterEstimates=est1&j; 
run; 
 
proc phreg data=newtwo&j; 
model TR1*status(0,1)=trt; 
ods output ParameterEstimates=est2&j; 
run;  
 
*Count number of event1 and event2 in the imputed dataset; 











* Create datasets containing estimates from all replic; 
%if &j=1 %then %do; 
    data p1; 
    set p1&j; 
    run; 
     
    data est1; 
    set est1&j; 
    run; 
 
    data est2; 
    set est2&j; 
    run; 
 
    data freq0; 
    set freq0&j; 
run; 
 
    data freq1; 






    data p1; 
    set p1 p1&j; 
    run; 
 
 
    data est1; 
    set est1 est1&j; 
    run; 
 
     data est2; 
     set est2 est2&j; 
     run; 
 
     data freq0; 
     set freq0 freq0&j; 
     run; 
 
     data freq1; 
     set freq1 freq1&j; 





















proc means data=p1(where=(status=1)); 
var percent; 
output out=resp1 mean=mp1; 
run; 
 
proc means data=est1; 
var Estimate var; 
output out=resevent1 mean=mbeta mvar; 
run; 
 
proc means data=est2; 
var Estimate var; 
output out=resevent2 mean=mbeta mvar; 
run; 
 
proc means data=freq0(where=(status=1)); 
var count; 
output out=resc10 mean=mf; 
run; 
 
proc means data=freq0(where=(status=2)); 
var count; 
output out=resc20 mean=mf; 
run; 
 
proc means data=freq1(where=(status=1)); 
var count; 
output out=resc11 mean=mf; 
run; 
 
proc means data=freq1(where=(status=2)); 
var count; 





(iii) SAS codes for the JM 
* Import the simulated dataset newone; 





* Apply the jiterring method to the tied failures; 
%macro replic; 
%do j = 1 %to 300; 
 
* Extract subjects without tied failures; 
data two&j; 
set one; 
if status ne 3; 














*  Jittering the time to event to deal with multiple first failures and 








if time1=time2 then goto repeat; 
 
 





* Reassignment of site of first failure after ties have been broken; 
 
if mintime=time1 then status=1; 
else if mintime=time2 then status=2; 
else status=0; 
 
keep id status trt TL1 TR1; 
run; 
 




proc append base=two&j data=four&j; 
run; 
 
* Cause-specific hazard regression analysis; 
proc phreg data=two&j; 
model TR1*status(0,2)=trt; 
ods output ParameterEstimates=est1&j; 
run; 
 
proc phreg data=two&j; 
model TR1*status(0,1)=trt; 
ods output ParameterEstimates=est2&j; 
run;  
 
*Count number of event1 and event2 in the imputed dataset; 










* Create datasets containing estimates from all replic; 
%if &j=1 %then %do; 
    data p1; 
    set p1&j; 
    run; 
 
    data est1; 
    set est1&j; 
    run; 
 
    data est2; 
    set est2&j; 
    run; 
 
    data freq0; 
    set freq0&j; 
    run; 
 
    data freq1; 
    set freq1&j; 




    data p1; 
    set p1 p1&j; 
    run; 
 
    data est1; 
    set est1 est1&j; 
    run; 
 
    data est2; 
    set est2 est2&j; 
    run; 
 
    data freq0; 
    set freq0 freq0&j; 
    run; 
 
    data freq1; 
    set freq1 freq1&j; 






















proc means data=p1(where=(status=1)); 
var percent; 
output out=resp1 mean=mp1; 
run; 
 
proc means data=est1; 
var Estimate var; 
output out=resevent1 mean=mbeta mvar; 
run; 
 
proc means data=est2; 
var Estimate var; 
output out=resevent2 mean=mbeta mvar; 
run; 
 
proc means data=freq0(where=(status=1)); 
var count; 
output out=resc10 mean=mf; 
run; 
 
proc means data=freq0(where=(status=2)); 
var count; 
output out=resc20 mean=mf; 
run; 
 
proc means data=freq1(where=(status=1)); 
var count; 
output out=resc11 mean=mf; 
run; 
 
proc means data=freq1(where=(status=2)); 
var count; 
output out=resc21 mean=mf; 
run; 
 
(iv) STATA codes for the WC method 
Event 1 
 
stset tr1 [pweight = weight], failure(status==1) 
 





stset tr1 [pweight = weight], failure(status==2) 
 








5. SAS and STATA codes for analysing the osteosarcoma data 
(i) SAS codes for the SF method 
* Import the osteo dataset; 





*Parameter estimation with variance theta; 
proc nlmixed data=one qpoints=30 noad; 
parms lambda1=0.45 lambda2=0.16 beta1=0 beta2=0 theta=3; 








if p>.999999 then p=.999999; 
g2=quantile('GAMMA',p,1/theta); 









array LogL {4} logL1-logL4; /*1-censored, 2-LM, 3-NLM, 4-tied */ 
 
do i=1 to 4; 
   logL{i}=0; 
end; 
 
if status=0 then logL1=log(sb*sd); 
if status=1 then logL2=log((sa-sb)*sd); 
if status=2 then logL3=log((sc-sd)*sb); 





model tr ~ general(loglik); 
random nu ~ normal(0, 1) subject=trialno; 






%do j = 1 %to 300; 
 
*Extract subjects without tied failures; 
data two&j; 
set one; 


















































keep id trialno time status trt2 trt tr tl; 
run; 
 
*Combine subjects without ties and those those with imputed first failures; 





*Evaluate the treatment effect by Cox proportional hazard function; 
proc phreg data=two&j; 
model time*status(0,2)=trt; 





proc phreg data=two&j; 
model time*status(0,1)=trt; 
ods output ParameterEstimates=nlung&j; 
run;  
 
*Count number of lung and non-lung in the imputed dataset; 
proc freq data=two&j; 
























* Create datasets containing estimates from all replic; 
%if &j=1 %then %do; 
 data p1; 
 set p1&j; 
 run; 
 
      data estlung; 
      set lung&j; 
      run; 
 
 data estnlung; 
 set nlung&j; 
 run; 
 
 data mnevents01; 
 set nevents01&j; 
 run; 
 
 data mnevents02; 
 set nevents02&j; 
 run; 
 
 data mnevents11; 
 set nevents11&j; 
 run; 
 
 data mnevents12; 







      data p1; 
 set p1 p1&j; 
 run; 
 
      data estlung; 
      set estlung lung&j; 
      run; 
 
 data estnlung; 
 set estnlung nlung&j; 
 run; 
 
 data mnevents01; 
 set mnevents01 nevents01&j; 
 run; 
 
 data mnevents02; 
 set mnevents02 nevents02&j; 
 run; 
 
 data mnevents11; 
 set mnevents11 nevents11&j; 
 run; 
 
 data mnevents12; 























proc means data=p1(where=(status=1)); 
var percent; 
output out=resp1 mean=mp1; 
run; 
 
proc means data=estlung; 
var Estimate varlung; 
output out=reslung1 mean=mbeta mvar; 
run; 
 
proc means data=estnlung; 
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var Estimate varnlung; 
output out=resnlung1 mean=mbeta mvar; 
run; 
 
proc means data=mnevents01; 
var count; 
output out=reslung2 mean=mf; 
run; 
 
proc means data=mnevents02; 
var count; 
output out=resnlung2 mean=mf; 
run; 
 
proc means data=mnevents11; 
var count; 
output out=reslung3 mean=mf; 
run; 
 
proc means data=mnevents12; 
var count; 





(ii) SAS codes for the JM  
*Read the osteosarcoma dataset into SAS; 





* Apply the jiterring method to the tied failures; 
%macro replic; 
%do j = 1 %to 300; 
 
* Extract subjects without tied failures; 
data two&j; 
set one; 
if status ne 3; 
run; 
 









*  Jittering the time to event to deal with multiple first failures and 










if time1=time2 then goto repeat; 
 
 





* Reassignment of site of first failure after ties have been broken; 
 
if mintime=time1 then status=1; 








proc append base=two&j data=four&j; 
run; 
 
* Cause-specific hazard regression analysis; 
proc phreg data=two&j; 
model tr*status(0,2)=trt; 
ods output ParameterEstimates=est1&j; 
run; 
 
proc phreg data=two&j; 
model tr*status(0,1)=trt; 
ods output ParameterEstimates=est2&j; 
run;  
 
*Count number of event1 and event2 in the imputed dataset; 








* Create datasets containing estimates from all replic; 
%if &j=1 %then %do; 
 data p1; 
 set p1&j; 
 run; 
 
      data est1; 
      set est1&j; 
      run; 
  
      data est2; 
 set est2&j; 
 run; 
 
 data freq0; 
 set freq0&j; 
 run; 
 
 data freq1; 
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set p1 p1&j; 
    run; 
 
    data est1; 
    set est1 est1&j; 
    run; 
 
    data est2; 
    set est2 est2&j; 
    run; 
 
    data freq0; 
    set freq0 freq0&j; 
    run; 
 
    data freq1; 
    set freq1 freq1&j; 




















proc means data=p1(where=(status=1)); 
var percent; 
output out=resp1 mean=mp1; 
run; 
 
proc means data=est1; 
var Estimate var; 
output out=resevent1 mean=mbeta mvar; 
run; 
 
proc means data=est2; 
var Estimate var; 
output out=resevent2 mean=mbeta mvar; 
run; 
 
proc means data=freq0(where=(status=1)); 
var count; 





proc means data=freq0(where=(status=2)); 
var count; 
output out=resc20 mean=mf; 
run; 
 
proc means data=freq1(where=(status=1)); 
var count; 
output out=resc11 mean=mf; 
run; 
 
proc means data=freq1(where=(status=2)); 
var count; 









stset tr [pweight = weight], failure(status==1) 
 





stset tr [pweight = weight], failure(status==2) 
 
stcox trt, vce(cluster trialno) nohr 
 
 
 
 
 
 
 
 
